🇺🇸 FDA

Intelligence · Clinical Pipeline

Takeda Pipeline

All ClinicalTrials.gov programs at Takeda — phase, modality, and trial IDs.

Programs
1,179

Quick answer

Takeda has 1,179 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. SSP-004184

    Takeda

    Hepatic Impairment

    phase 1 small molecule completed

    1 trial

  2. SSP-004184

    Takeda

    Impaired Renal Function

    phase 1 small molecule completed

    1 trial

  3. SSP-004184AQ

    Takeda

    Healthy

    phase 1 small molecule completed

    1 trial

  4. SSP-004184SS

    Takeda

    Healthy

    phase 1 small molecule completed

    1 trial

  5. SYR-472

    Takeda

    Healthy

    phase 1 small molecule completed

    1 trial

  6. Sapanisertib

    Takeda

    Non-hematologic Malignancy

    phase 1 small molecule completed

    1 trial

  7. Scopolamine

    Takeda

    Healthy Volunteers

    phase 1 small molecule terminated

    1 trial

  8. Simvastatin

    Takeda

    Healthy

    phase 1 small molecule completed

    1 trial

  9. Soticlestat

    Takeda

    Healthy Volunteers

    phase 1 small molecule terminated

    4 trials

  10. Soticlestat

    Takeda

    Hepatic Impairment

    phase 1 small molecule completed

    1 trial

  11. Soticlestat 300 mg

    Takeda

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  12. TAK-004

    Takeda

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  13. TAK-007

    Takeda

    Refractory Lupus Nephritis

    phase 1 mab terminated

    1 trial

  14. TAK-020

    Takeda

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  15. TAK-020 Captisol Oral Solution

    Takeda

    Healthy

    phase 1 small molecule completed

    1 trial

  16. TAK-058

    Takeda

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  17. TAK-058

    Takeda

    Schizophrenia

    phase 1 small molecule terminated

    1 trial

  18. TAK-058 (ENV8058)

    Takeda

    Dose Finding Study

    phase 1 small molecule completed

    1 trial

  19. TAK-063

    Takeda

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  20. TAK-063

    Takeda

    Schizophrenia

    phase 1 small molecule completed

    1 trial

  21. TAK-071

    Takeda

    Alzheimer Disease

    phase 1 small molecule terminated

    1 trial

  22. TAK-079

    Takeda

    Systemic Lupus Erythematosus

    phase 1 small molecule completed

    1 trial

  23. TAK-079

    Takeda

    Multiple Myeloma

    phase 1 small molecule completed

    1 trial

  24. TAK-079

    Takeda

    Autoimmune Disease

    phase 1 small molecule completed

    1 trial

  25. TAK-102

    Takeda

    Solid Tumors

    phase 1 mab terminated

    1 trial

  26. TAK-103

    Takeda

    Solid Tumors

    phase 1 mab terminated

    1 trial

  27. TAK-105-a

    Takeda

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  28. TAK-114 10 mg capsule

    Takeda

    Clinical Pharmacology

    phase 1 small molecule completed

    1 trial

  29. TAK-117

    Takeda

    Neoplasm, Advanced or Metastatic

    phase 1 small molecule completed

    1 trial

  30. TAK-117

    Takeda

    Metastatic Solid Tumors

    phase 1 small molecule completed

    1 trial

  31. TAK-123

    Takeda

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  32. TAK-137

    Takeda

    Attention-Deficit/Hyperactivity Disorder

    phase 1 small molecule terminated

    1 trial

  33. TAK-137

    Takeda

    Dose Finding Study

    phase 1 small molecule completed

    1 trial

  34. TAK-137 5 mg tablet, TAK-137 placebo tablet

    Takeda

    Healthy Japanese Adult Male

    phase 1 small molecule terminated

    1 trial

  35. TAK-164

    Takeda

    Gastrointestinal Neoplasms; Esophageal, Stomach, Pancreas, Colon Neoplasms; Malignant Tumors of Digestive Organ; Advanced Gastrointestinal Malignancies

    phase 1 small molecule terminated

    1 trial

  36. TAK-165

    Takeda

    Breast Neoplasm

    phase 1 small molecule completed

    1 trial

  37. TAK-227

    Takeda

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  38. TAK-228

    Takeda

    Advanced Nonhematologic Malignancies

    phase 1 small molecule completed

    1 trial

  39. TAK-233

    Takeda

    Clinical Pharmacology

    phase 1 small molecule completed

    1 trial

  40. TAK-272

    Takeda

    Japanese Healthy Adult Males

    phase 1 small molecule completed

    1 trial

  41. TAK-272

    Takeda

    Renal Impairment

    phase 1 small molecule completed

    1 trial

  42. TAK-279

    Takeda

    Renal Impairment

    phase 1 small molecule completed

    1 trial

  43. TAK-279

    Takeda

    Hepatic Impairment

    phase 1 small molecule completed

    1 trial

  44. TAK-279

    Takeda

    Healthy Volunteers

    phase 1 small molecule completed

    3 trials

  45. TAK-329

    Takeda

    Type 1 Diabetes Mellitus

    phase 1 small molecule completed

    1 trial

  46. TAK-385

    Takeda

    Hormone Treatment-naïve Participants With Prostate Cancer

    phase 1 small molecule completed

    1 trial

  47. TAK-385 40 mg

    Takeda

    Japanese Premenopausal Healthy Adult Women

    phase 1 small molecule completed

    1 trial

  48. TAK-385 T2 Formulation

    Takeda

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

Frequently asked questions

How many pipeline programs does Takeda have?

1,179 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.